Use of Ritlecitinib for the Treatment of Alopecia Areata

Ritlecitinib, a JAK3 and TEC inhibitor, has been approved by the FDA for treating alopecia areata, an autoimmune condition causing hair loss. Unlike Baricitinib, Ritlecitinib is safe for patients aged 12 and older, making it a significant option for younger individuals. The ALLEGRO Phase 2b/3 trial demonstrated that 50 mg of Ritlecitinib daily for 24 weeks resulted in 80% or more scalp hair coverage in treated patients compared to a placebo. Common side effects include headache, respiratory infections, and gastrointestinal issues. Ritlecitinib offers a less invasive treatment with fewer side effects compared to other therapies.